Explore The Possibility of
Changing Your Classic CAH Journey
Find A Trial Site Near You
Available Trial Sites
United States
| State | City | Site/Institution |
| AL | Birmingham | University of Alabama at Birmingham |
| CA | San Diego | University of California, San Diego – Rady Children’s Hospital |
| CA | Orange | Childrens Hospital of Orange County |
| CA | Sacramento | Center of Excellence in Diabetes and Endocrinology (CEDE) |
| CO | Englewood | Denver Endocrinology Diabetes and Thyroid Center |
| FL | Tampa | University of South Florida |
| IL | Chicago | Northwestern University |
| IN | Indianapolis | Indiana University (IU) School of Medicine – University Hospital |
| MA | Boston | Tufts Medical Center |
| MD | Baltimore | Johns Hopkins Hospital |
| MD | Camp Springs | Capital Diabetes & Endocrine Associate |
| MN | Minneapolis | University of Minnesota |
| MN | Rochester | Mayo Clinic – Rochester |
| NC | Charlotte | OnSite Clinical Solutions, LLC |
| NJ | Newark | Rutgers New Jersey Medical School |
| NV | Las Vegas | Palm Research Center, Inc. |
| NY | Syracuse | SUNY Upstate Medical University |
| OH | Cleveland | Cleveland Clinic |
| OH | Columbus | Ohio State University Medical Center (OSUMC) – Division of Endocrinology |
| OH | Canton | Diabetes and Endocrinology Associates of Stark County |
| OK | Oklahoma City | Unity Clinical Research |
| OR | Bend | Endocrinology Services Northwest |
| PA | Philadelphia | The Children’s Hospital of Philadelphia |
| PA | Philadelphia | Thomas Jefferson University |
| PA | Philadelphia | Temple University Hospital |
| SC | Columbia | Prisma Health Midlands |
| TN | Memphis | University Of Tennessee Health Science Center – Division of Endocrinology, Diabetes & Metabolism |
| TX | Fort Worth | Cook Childrens Medical Center |
| TX | Edinburg | DHR Health Institute for Research and Development |
| TX | Dallas | Research Institute of Dallas |
| WA | Seattle | Seattle Children’s Hospital |
Outside of the United States
| State | City | Site/Institution |
| Australia | Camperdown | Royal Prince Alfred Hospital |
| Australia | Elizabeth Vale | Lyell McEwin Hospital |
| Australia | Nedlands | Keogh Institute for Medical Research |
| Australia | NSW | Blacktown Hospital |
| Australia | Parkville | Melbourne Health – Royal Melbourne Hospital |
| Canada | London, Ontario | St. Joseph’s Health Care – London |
| Canada | Ottawa, Ontario | University of Ottawa |
| Canada | Sherbrooke, Quebec | Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l’Estrie -Centre hospitalier universitaire de Sherbrooke (CHUS) |
| Canada | St John’s, Newfoundland and Labrador | Eastern Regional Health Authority Health Sciences Centre |
| Denmark | Aarhus | Aarhus University Hospital |
| Denmark | Copenhagen | Rigshospitalet |
| Germany | Munich | Klinikum der Universitaet Muenchen – Campus Innenstadt |
| Italy | Milano | IRCCS Ospedale San Raffaele |
| Italy | Rome | Azienda Ospedaliero-Universitaria Sant’Andrea |
| Italy | Rome | Fondazione Policlinico Universitario A. Gemelli IRCCS – Universita Cattolica del Sacro Cuore |
| Netherlands | Nijmegen | Stichting Radboud Universitair Medisch Centrum |
| Poland | Krakow | SP ZOZ Szpital Uniwersytecki w Krakowie, Ambulatoria Uniwersyteckie, Zespól Poradni NSSU, Poradnia Endokrynologiczn |
| Spain | Barcelona | Hospital Universitario Vall d’Hebron |
| Spain | Madrid | Hospital General Universitario Gregorio Maranon |
| Spain | Sevilla | Hospital Universitario Virgen del Rocio |
| Sweden | Falun | Falun Hospital |
| Sweden | Stockholm | Karolinska University Hospital |
| United Kingdom | Birmingham | University of Birmingham |
| United Kingdom | Liverpool | Royal Liverpool University Hospital |
| United Kingdom | London | St George’s Hospital |
Am I Eligible?
Before a medication can be prescribed by a health care provider, it must be tested. Clinical trial programs are health-related research studies in humans that follow a pre-defined, detailed plan to determine the safety and effectiveness of the investigational medication for its intended use.
The primary purpose of the CAHmelia program is to assess if tildacerfont is effective in lowering androgens (testosterone-related hormones) and daily glucocorticoid doses in adults with classic CAH. The CAHmelia studies are dedicated to exploring solutions for people living with classic CAH.(4,5)
Living with classic Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia (CAH) is a rare genetic condition that affects the body’s ability to create and regulate key hormones. Most significantly, CAH alters the production of cortisol, which is known as the “stress hormone.” CAH also affects the production of aldosterone, which regulates salt and water balance in your body, and androgens which are testosterone-related hormones present in men and women.(1)
Managing CAH
Do you live with classic Congenital Adrenal Hyperplasia (CAH)?
Currently, glucocorticoid (GC) therapy is the only approved treatment for classic CAH. GCs are a type of steroid treatment that can help you manage your condition by replacing deficient cortisol and reducing androgen levels.(2)
Replacing cortisol with steroids is necessary to maintain health in people with classic CAH. However, many people with classic CAH also need steroids to decrease their androgen production to control symptoms such as excess body hair, fertility challenges, irregular menstrual periods, and testicular adrenal rest tumors (TARTS).(2)
Steroid therapy goals are to prevent life-threatening adrenal crisis across all ages, provide balanced hormone levels and promote normal growth and development.
To learn more about the condition of classic Congenital Adrenal Hyperplasia (CAH), watch these videos with SpruceBio Chief Medical Officer and Endocrinologist, Dr. Will Charlton.
Meet SpruceBio Chief Medical Officer, Dr. Will Charlton as he discusses classic Congenital Adrenal Hyperplasia (CAH) and it’s effects on patients.
Glucocorticoid related signs and symptoms to W.A.T.C.H.
Weight Gain • Appetite lncrease • Temperament/Mood Changes • Circular or Moon Face • Hair Growth & Acne (facial)
Your body may be sending you a message about hormone imbalance from glucocorticoid (steroid) under-treatment or over-treatment.(1)
A survey of 113 CAH participants stated that they do not feel sufficiently informed about their treatment:*
51% of participants felt they did not have enough access to information to make an informed choice about GC treatment
66% of participants are willing to change their current regimen if they could lower their dose of steroid
*Data on file Spruce Biosciences Participant Survey 2022
A survey of 113 CAH participants reported that side-effects are common*
64% Weight Gain
47% Fatigue
36% Mood Swings
33% Depression
*Data on file Spruce Biosciences Participant Survey 2022
What is tildacerfont?
Tildacerfont is a new type of oral, once-daily investigational drug that is NOT a steroid.(3) By reducing the amount of androgens (testosterone-related hormones) your body makes, tildacerfont may improve your classic CAH symptoms.(3) This investigational drug will not replace your steroid treatment but may allow you to manage your condition with lower amounts of steroids.
Is tildacerfont safe?
Tildacerfont is generally well-tolerated in healthy volunteers and in people with classic CAH:
- Generally well-tolerated at doses under evaluation
- Generally well-tolerated across a diverse group of people
Tildacerfont is generally well-tolerated in healthy volunteers and people with classic CAH. Tildacerfont’s global history includes 8 studies with 230 participants, in 92 centers, and 20 countries.
Who can take part in this Study?
You may be able to take part if you*:
- Are at least 18 years of age
- Have a confirmed diagnosis of classic CAH due to 21-OH deficiency
- Take steroids daily (glucocorticoids with or without mineralocorticoids)
- Taking part is completely voluntary, and you may choose to stop at any time.
*Other criteria applies
What can I expect if I enroll?
Before the Study
Evaluations will be done (either at the clinic and/or at home) to see if you can take part in the trial.
During the Study
You will be chosen at random to receive either tildacerfont or a placebo (inactive pill). After the placebo period, everyone will receive tildacerfont. Visits and laboratory tests (blood and/or urine) will be done regularly during the study to monitor the safety of your treatment. Flexible visit options based on patient preferences include in-office, telemedicine, or home visits.
Travel reimbursement is available to support you in attending your study visits if needed. Please reach out to our study team to learn more about this option. Home health visits and home delivery of study drug may also be available, depending on what your site can offer.
The CAHmelia program is dedicated to exploring solutions for the symptoms that matter most to you. For more information about the CAHmelia Study Journey, Click on our Study logos.
Please review our CAHmelia Study Informational Brochure below.
CAHmelia Informational Brochure
To see if you qualify for the CAHmelia Study, click here to answer a few questions.
Finding the support you need
The Spruce Patient Engagement Team
Living with a rare endocrine condition can be a complex journey you don’t have to navigate alone. The Spruce Patient Engagement Team offers personalized support and access to resources for people living with classic CAH.
Spruce Patient Engagement Liaisons (PELs) work closely with individuals, families, advocacy groups, and healthcare providers to better understand the needs of these communities. PELs provide education and resources related to these conditions, and serves as a contact resource for local advocacy and support groups.
“I am proud to serve as a trusted resource and
advocate for members of this community.”
– Mara VanAndel
Connecting with organizations and local support groups can help people understand more about their condition and meet others in the CAH community.
These groups and websites are neither owned nor controlled by Spruce Biosciences. Spruce does not endorse and is not responsible for the content or services they provide.
The purpose of the Spruce Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers. PELs are employees of Spruce Biosciences. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your healthcare team.
FAQ’s
Review our CAHmelia Study FAQ’s
Who qualifies for the CAHmelia Studies?
18 years of age and older and diagnosed with classic congenital adrenal hyperplasia.
Can I participate if I have non-classic CAH?
At this time, only individuals with classic CAH (including salt-wasting and simple virilizing) due to 21-hydroxylase deficiency are eligible for the CAHmelia studies.
Who is conducting the CAHmelia studies?
The CAHmelia studies are sponsored by Spruce Biosciences across 20 different countries, including the United States, Canada, Europe, South America, Asia and Australia.
Where will my study visits take place?
In certain circumstances, you can choose to have home health-care visits or telemedicine appointments instead of visits that would normally be in the clinic. For some tests, you will need to visit the clinic.
Will participants stop taking steroid treatment when starting tildacerfont?
Participants will NOT stop taking steroid treatment. Tildacerfont will not replace your steroid treatment but may allow you to manage your condition with lower doses of steroids.
What if I want to stop participating in the CAHmelia study?
Participation in CAHmelia studies are completely voluntary, you can freely withdraw (discontinue participation) at any time during the clinical trial.
What does it cost?
CAHmelia participants will receive CAHmelia study-related care, including medical tests, clinical care, stress-dosing steroids, and tildacerfont at no cost. Home health visits and home delivery of study drug may also be available, depending on what your site can offer.
References:1. Claahsen-van der Grinten HL, et al. Endocr Rev. 2022;43(1):91-159.doi: 10.1210/endrev/ bnab016; 2. Speiser PW, et al. J Clin Endocrinol Metab. 2018;103:4043–88; 3.Sarafoglou K,et al. J Clin Endocrinol Metab. 2021;106(11):e4666-e4679. doi:10.1210/clinem/dgab438;4. ClinicalTrials.gov. NCT04544410. Available at: https://clinicaltrials.gov/ct2/show/NCT04544410 (accessed May 23, 2022); 5. ClinicalTrials.gov.NCT04457336. Available at: https://clinicaltrials.gov/ct2/show/NCT04457336 (accessed May 23, 2022).
SPRUCE BIOSCIENCES, INC.
611 Gateway Blvd
Suite 740
South San Francisco, CA 94080 USA
©2023 Spruce Biosciences, Inc. All Rights Reserved